Raimo Virtanen - Concepedia

Author

Raimo Virtanen

Orion Corporation (Finland)

Also Known As

RAIMO VIRTANEN, Raimo Virtanen

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Orion Corporation (Finland)University of Eastern Finland University of Turku Orion Corporation (United Kingdom)University of Helsinki

About

Raimo Virtanen is an author at Orion Corporation (Finland) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	21	1.4K
2	Social Sciences	11	11	326
3	Anesthesia	5	5	882
4	Health Sciences	3	3	96
5	Natural Sciences	1	1	41

Raimo Virtanen

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Characterization of the selectivity, specificity and potency of medetomidine as an α2-adrenoceptor agonist Raimo Virtanen, Juha‐Matti Savola, Veijo Saano, European Journal of Pharmacology Molecular PharmacologyFunctional SelectivityMedicinePhysiologyNeuropharmacology	1988	691
Central α2-adrenoceptors are highly stereoselective for dexmedetomidine, the dextro enantiomer of medetomidine Juha‐Matti Savola, Raimo Virtanen European Journal of Pharmacology Molecular PharmacologyAdrenal GlandMedicineDextro EnantiomerNeuroendocrine Disorder	1991	137
Effects of Dexmedetomidine, a Novel Imidazole Sedative-Anesthetic Agent, on Adrenal Steroidogenesis Mervyn Maze, Raimo Virtanen, David A. Daunt, Anesthesia & Analgesia Imidazole CompoundsMedicinal ChemistryAdrenal GlandPharmacological StudyMedicine	1991	95
Evaluation of the effects of a specific α2-adrenoceptor antagonist, atipamezole, on α1- and α2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine Antti Haapalinna, Timo Viitamaa, Ewen MacDonald, Naunyn-Schmiedeberg s Archives of Pharmacology Molecular PharmacologyBehavioral NeuroscienceMedicineBehavioural PharmacologyBehavioral Pharmacology	1997	86
Comparison of the effects of detomidine and xylazine on some α2-adrenoceptor-mediated responses in the central and peripheral nervous systems Raimo Virtanen, Ewen MacDonald European Journal of Pharmacology Molecular PharmacologyNeurophysiologyMedicinePhysiologyPeripheral Nervous Systems	1985	53
Evaluation of the α1- and α2-adrenoceptor effects of detomidine, a novel veterinary sedative analgesic Raimo Virtanen, Leena Nyman European Journal of Pharmacology Pain MedicineMedicinePhysiologyAnesthesia PracticeExperimental Pharmacology	1985	46
Protean Agonism at α2A-Adrenoceptors Christian Jansson, Jyrki P. Kukkonen, Johnny Näsman, Molecular Pharmacology Molecular PharmacologyAdrenal GlandSignal TransductionMolecular PhysiologyBiochemistry	1998	41
Pharmacological Characterisation of a Structurally Novel α<sub>2C</sub> ‐Adrenoceptor Antagonist <scp>ORM</scp>‐10921 and its Effects in Neuropsychiatric Models Jukka Sallinen, Johanna Holappa, Ari Koivisto, Basic & Clinical Pharmacology & Toxicology Psychotropic MedicationPsychopharmacologyPharmacotherapyExperimental PharmacologySocial Sciences	2013	40
Medetomidine, a new sedative and analgesic drug for dogs and cats: A Summary Outi Vainio, Liisa Palmu, Raimo Virtanen, Journal of the Association of Veterinary Anaesthetists of Great Britain and Ireland Health SciencesPain MedicineMedicineVeterinary ScienceAnesthesia Practice	1986	38
Effects of acute GR38032F (odansetron), a 5-HT3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons Markku Koulo, Birgitta Sjöholm, Jaakko Lappalainen, European Journal of Pharmacology Serotonin MetabolismNigrostriatal Dopaminergic NeuronsNeurophysiologyMedicinePsychopharmacology	1989	28

Page 1